Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin vs ASCT in Relapsed/Refractory Follicular Lymphoma
NCT01827605Phase 3Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jan 2012
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibritumomab tiuxetan in follicular lymphoma (FL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression Free Survival from randomization at 36 months. Started Jan 2012; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01827605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827605.